ATE209045T1 - Hepatitis b impfstoff - Google Patents
Hepatitis b impfstoffInfo
- Publication number
- ATE209045T1 ATE209045T1 AT96904814T AT96904814T ATE209045T1 AT E209045 T1 ATE209045 T1 AT E209045T1 AT 96904814 T AT96904814 T AT 96904814T AT 96904814 T AT96904814 T AT 96904814T AT E209045 T1 ATE209045 T1 AT E209045T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccine
- hepatitis
- Prior art date
Links
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9503863.4A GB9503863D0 (en) | 1995-02-25 | 1995-02-25 | Vaccine compositions |
| PCT/EP1996/000681 WO1996026741A1 (en) | 1995-02-25 | 1996-02-15 | Hepatitis b vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE209045T1 true ATE209045T1 (de) | 2001-12-15 |
Family
ID=10770292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96904814T ATE209045T1 (de) | 1995-02-25 | 1996-02-15 | Hepatitis b impfstoff |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US5972346A (de) |
| EP (1) | EP0810877B1 (de) |
| JP (1) | JP3881015B2 (de) |
| KR (1) | KR100365373B1 (de) |
| CN (1) | CN1101225C (de) |
| AP (1) | AP766A (de) |
| AR (1) | AR002279A1 (de) |
| AT (1) | ATE209045T1 (de) |
| AU (1) | AU695921B2 (de) |
| BG (1) | BG101851A (de) |
| BR (1) | BR9607458A (de) |
| CA (1) | CA2212552C (de) |
| CZ (1) | CZ288417B6 (de) |
| DE (1) | DE69617211T2 (de) |
| DK (1) | DK0810877T3 (de) |
| EA (1) | EA199700126A1 (de) |
| ES (1) | ES2166879T3 (de) |
| FI (1) | FI118118B (de) |
| GB (1) | GB9503863D0 (de) |
| HK (1) | HK1004117A1 (de) |
| HU (1) | HU224832B1 (de) |
| IL (1) | IL117249A (de) |
| MA (1) | MA23814A1 (de) |
| MX (1) | MX9706450A (de) |
| MY (1) | MY113428A (de) |
| NO (1) | NO319394B1 (de) |
| NZ (1) | NZ302674A (de) |
| OA (1) | OA10612A (de) |
| PL (1) | PL182679B1 (de) |
| PT (1) | PT810877E (de) |
| SA (1) | SA96160633B1 (de) |
| SK (1) | SK115097A3 (de) |
| TR (1) | TR199700849T1 (de) |
| TW (1) | TW467745B (de) |
| WO (1) | WO1996026741A1 (de) |
| ZA (1) | ZA961460B (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620414B2 (en) * | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| US6488934B1 (en) * | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| US20010014331A1 (en) * | 1996-11-07 | 2001-08-16 | Smithkline Beecham Biologicals S.A. | Acellular pertussis vaccine with diphthriae-and tetanus-toxoids |
| US20030049268A1 (en) | 1998-05-01 | 2003-03-13 | Smithkline Beecham Biologicals S.A. | Novel composition |
| GB9809507D0 (en) * | 1998-05-01 | 1998-07-01 | Smithkline Beecham Biolog | Novel composition |
| DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| TR200101055T2 (tr) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
| CU22871A1 (es) * | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
| CA2355680A1 (en) * | 1998-12-23 | 2000-06-29 | Qinjian Zhao | Improved recombinant hepatitis b surface antigen |
| EP2322210A1 (de) | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvans Zusammensetzung enthaltend Saponin und ein Immunstimulatorisches Oligonukleotid |
| US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| CU23031A1 (es) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
| AP2007004151A0 (en) * | 2005-02-16 | 2007-10-31 | Norvatis Vaccines And Diagnost | Adjuvant composition comprising aluminium phosphate and 3D-MPL |
| EA014314B1 (ru) * | 2005-08-02 | 2010-10-29 | Новартис Вэксинес Энд Дайэгностикс Срл | Пониженная интерференция между маслосодержащими адъювантами и антигенами, содержащими поверхностно-активные вещества |
| NZ592713A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 |
| DK2368572T3 (da) | 2005-11-04 | 2020-05-25 | Seqirus Uk Ltd | Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur |
| JP2009514850A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
| PT1951299E (pt) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores |
| CN100415294C (zh) * | 2005-12-23 | 2008-09-03 | 中国农业大学 | 一种治疗和/或预防乙肝的药物 |
| EP2478916B1 (de) | 2006-01-27 | 2020-04-01 | Seqirus UK Limited | Influenzaimpfstoffe mit Hämagglutinin und Matrixproteinen |
| EP2010537B1 (de) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazochinoxalinverbindungen als immunmodulatoren |
| EP2382987A1 (de) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Lagerung von Influenza-Impfstoffen ohne Kühlung |
| EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| AU2007297178B2 (en) | 2006-09-11 | 2014-07-24 | Novartis Ag | Making influenza virus vaccines without using eggs |
| CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| NZ582595A (en) | 2007-06-27 | 2012-07-27 | Novartis Ag | Low-additive influenza vaccines |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| CN101971030A (zh) | 2007-12-24 | 2011-02-09 | 诺华有限公司 | 流感吸附疫苗的试验 |
| SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
| HUE043879T2 (hu) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | RSV-immunizálási rend |
| US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
| US20140248314A1 (en) | 2011-05-13 | 2014-09-04 | Novartis Ag | Pre-fusion rsv f antigens |
| WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE69031556T2 (de) * | 1989-07-25 | 1998-05-14 | Smithkline Beecham Biolog | Antigene sowie Verfahren zu deren Herstellung |
| ATE168545T1 (de) * | 1991-05-29 | 1998-08-15 | Origin Medsystems Inc | Retraktor-vorrichtung fuer endoskopische chirurgie |
| MY111880A (en) * | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
| DE69334297D1 (de) * | 1992-05-23 | 2009-11-12 | Glaxosmithkline Biolog Sa | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
| EP0812593B8 (de) * | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | 3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen |
| GB9311536D0 (en) * | 1993-06-04 | 1993-07-21 | Unilever Plc | Hot soluble low density extractable food product |
-
1995
- 1995-02-25 GB GBGB9503863.4A patent/GB9503863D0/en active Pending
-
1996
- 1996-02-14 MY MYPI96000567A patent/MY113428A/en unknown
- 1996-02-15 CN CN96192146A patent/CN1101225C/zh not_active Expired - Fee Related
- 1996-02-15 EP EP96904814A patent/EP0810877B1/de not_active Expired - Lifetime
- 1996-02-15 PL PL96321966A patent/PL182679B1/pl unknown
- 1996-02-15 EA EA199700126A patent/EA199700126A1/ru unknown
- 1996-02-15 ES ES96904814T patent/ES2166879T3/es not_active Expired - Lifetime
- 1996-02-15 DE DE69617211T patent/DE69617211T2/de not_active Expired - Lifetime
- 1996-02-15 AT AT96904814T patent/ATE209045T1/de active
- 1996-02-15 CA CA002212552A patent/CA2212552C/en not_active Expired - Fee Related
- 1996-02-15 JP JP52598896A patent/JP3881015B2/ja not_active Expired - Fee Related
- 1996-02-15 SK SK1150-97A patent/SK115097A3/sk unknown
- 1996-02-15 HU HU9801242A patent/HU224832B1/hu not_active IP Right Cessation
- 1996-02-15 AU AU48780/96A patent/AU695921B2/en not_active Ceased
- 1996-02-15 AP APAP/P/1997/001060A patent/AP766A/en active
- 1996-02-15 WO PCT/EP1996/000681 patent/WO1996026741A1/en active IP Right Grant
- 1996-02-15 DK DK96904814T patent/DK0810877T3/da active
- 1996-02-15 US US08/894,643 patent/US5972346A/en not_active Expired - Lifetime
- 1996-02-15 KR KR1019970705880A patent/KR100365373B1/ko not_active IP Right Cessation
- 1996-02-15 CZ CZ19972674A patent/CZ288417B6/cs not_active IP Right Cessation
- 1996-02-15 TR TR97/00849T patent/TR199700849T1/xx unknown
- 1996-02-15 NZ NZ302674A patent/NZ302674A/xx not_active IP Right Cessation
- 1996-02-15 PT PT96904814T patent/PT810877E/pt unknown
- 1996-02-15 BR BR9607458A patent/BR9607458A/pt not_active IP Right Cessation
- 1996-02-22 AR ARP960101469A patent/AR002279A1/es active IP Right Grant
- 1996-02-23 ZA ZA961460A patent/ZA961460B/xx unknown
- 1996-02-23 IL IL11724996A patent/IL117249A/xx not_active IP Right Cessation
- 1996-02-23 MA MA24171A patent/MA23814A1/fr unknown
- 1996-02-26 TW TW085102154A patent/TW467745B/zh not_active IP Right Cessation
- 1996-03-02 SA SA96160633A patent/SA96160633B1/ar unknown
-
1997
- 1997-08-02 OA OA70066A patent/OA10612A/en unknown
- 1997-08-22 FI FI973457A patent/FI118118B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973873A patent/NO319394B1/no not_active IP Right Cessation
- 1997-08-22 MX MX9706450A patent/MX9706450A/es unknown
- 1997-08-25 BG BG101851A patent/BG101851A/xx unknown
-
1998
- 1998-04-28 HK HK98103600A patent/HK1004117A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE209045T1 (de) | Hepatitis b impfstoff | |
| NO976060D0 (no) | Vaksiner mot hepatitt C | |
| NO20003302D0 (no) | Vaksine | |
| BR9711853A (pt) | Vacinas | |
| KR970704468A (ko) | 폴리에피토프 백신(polyepitope vaccines) | |
| ID20399A (id) | Vaksin influensa | |
| DE69126606T2 (de) | Vakzine | |
| DK0736303T3 (da) | Interferonopløsning | |
| DE69510024T2 (de) | Spritze | |
| DE69630611D1 (de) | Antigenische präparationen | |
| DE69509766D1 (de) | Mikroemulsionen | |
| IT1276662B1 (it) | Vaccini polinucleotidici | |
| NO933600D0 (no) | Termostabile virus | |
| DE29504168U1 (de) | Formularsatz | |
| ITMI950511A0 (it) | Fotodensitometro parallelo perfezionato | |
| SI0810877T1 (en) | Hepatitis b vaccine | |
| DE69326536T2 (de) | Antitumor Impfstoff | |
| FI944558A0 (fi) | Virus | |
| UA24703A (uk) | Емітерний повторювач | |
| NO980721D0 (no) | Vaksiner | |
| BR7502544U (pt) | Easy baby | |
| KR970703417A (ko) | 유두종 바이러스 백신(Papillomavirus vaccines) | |
| SE9501165D0 (sv) | Hållaranordning | |
| BR7500363U (pt) | Formulário | |
| KR960036267U (ko) | 세척기 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |